Bausch + Lomb Corporation Common Shares (BLCO)

Bausch + Lomb's efforts to sell have so far been unsuccessful. Meanwhile, KKR is aggressively pursuing a deal for Fuji Soft.

Dental supply maker Patterson Companies Inc announced Thursday that it is exploring strategic options, including a sale or merger, to boost shareholder value.

The highly indebted healthcare stock rose on rumors it may be selling itself.

The unfolding week's market trajectory depends on earnings from bellwether tech stocks and what the Fed has to say following its July meeting.

IMG tennis assets are on the auction block. The announcement came after TKO inked a deal with Endeavor for Professional Bull Riders.

S&P Global's Joe Mantone puts the latest M&A data in perspective and how deal pros might react post-Election Day.

It was quite a busy and eventful day for the company.

Private equity giants TPG and Blackstone are pursuing a potential $14 billion buyout of Bausch + Lomb.

Federal Reserve's rate cut boosted tech, construction, industrial, machinery, and financial sectors. Top-performing mid-cap stocks last week.

Bausch + Lomb is exploring a sale as its parent company, Bausch Health, faces significant debt and creditors' opposition to a spin-off.

Bausch + Lomb is reportedly considering a sale. But its potential acquirers could come up against antitrust concerns.

Tech stocks soared to their best session in five months on Wednesday, ahead of the highly anticipated Federal Open Market Committee (FOMC) meeting.

Clearside Biomedical pioneers suprachoroidal drug delivery for precise, effective treatment of retinal diseases. Oppenheimer rates CLSD Outperform with a $5 target, citing its innovative SCS Microinjector and strategic partnerships.

Tech optimism is likely to abound on Wall Street as AI-levered stocks are feeding off the strength generated by Advanced Micro Devices, Inc.‘s (NASDAQAMD)

For investors seeking stable and growing opportunities, eye care stocks are an attractive option.

BLCO stock results show that Bausch & Lomb met analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.